CELC
Celcuity LLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.80B
P/E Ratio
—
EPS
$-3.79
Beta
0.42
52W High
$129.09
52W Low
$9.51
50-Day MA
$113.87
200-Day MA
$83.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-172.02M |
| Operating Margin | 0.00% |
| Return on Equity | -163.80% |
| Return on Assets | -30.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.08 |
| Price-to-Book | 57.72 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -7.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $48.34M |
| Float | $29.66M |
| % Insiders | 10.21% |
| % Institutions | 98.25% |
Historical Volatility
HV 10-Day
69.94%
HV 20-Day
60.13%
HV 30-Day
66.49%
HV 60-Day
52.92%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($130.55 target)
1
Strong Buy9
Buy1
HoldData last updated: 4/29/2026